Rectourethral Fistula and Massive Rectal Bleeding from Iodine0125 Prostate Brachytherapy: A Case Report

Cherr, Gregory S.; Waters, Gregory S.; Hall, Craig; Pineau, Benoit C.
February 2001
American Surgeon;Feb2001, Vol. 67 Issue 2, p131
Academic Journal
Case Study
Iodine-125 brachytherapy is an effective well-tolerated treatment for localized prostate cancer. Gastrointestinal complications of brachytherapy (minor rectal bleeding or tenesmus) are uncommon. Rectal ulceration or rectourethral fistulas after prostate brachytherapy are rare. We present a case of massive refractory rectal bleeding and rectourethral fistula, a complication of prostate brachytherapy never before reported. As a result of the patient's life-threatening symptoms aggressive surgical therapy was necessary.


Related Articles

  • Complications and Functional Results of Surgery for Locally Advanced Prostate Cancer. Joniau, S. G.; Van Baelen, A. A.; Hsu, C. Y.; Van Poppel, H. P. // Advances in Urology;2012, p1 

    The role of surgery in clinical stage T3 prostate cancer (cT3 PCa) is still subject to debate. We reviewed the records of 139 consecutive patients who underwent a radical prostatectomy (RP) for cT3 PCa with a mean follow-up of 8 years. All data related to surgical and perioperative complications...

  • Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma. Inokuchi, Haruo; Mizowaki, Takashi; Norihisa, Yoshiki; Takayama, Kenji; Ikeda, Itaru; Nakamura, Kiyonao; Nakamura, Mitsuhiro; Hiraoka, Masahiro // International Journal of Clinical Oncology;Feb2016, Vol. 21 Issue 1, p156 

    Background: Several studies have confirmed a dosimetric advantage associated with use of a smaller leaf in intensity-modulated radiation therapy (IMRT). However, no studies have identified any clinical benefits. We investigated the effect of a smaller multileaf collimator (MLC) width on the...

  • Early prostate cancer best left alone--Treatment riskier than cancer.  // HealthFacts;Jul93, Vol. 18 Issue 170, p1 

    Reports on the modalities of treating prostatic cancer. Prostate Patient Outcomes Research Team; Radical prostatectomy; Prostate-specific antigen blood test; Radiation therapy; Watchful waiting; Nerve-sparing technique.

  • Patients say they want aggressive treatment for prostate cancer.  // Modern Medicine;Jul96, Vol. 64 Issue 7, p31 

    Reports that a Harris Poll survey of 1,000 newly diagnosed patients has found that men who have prostate cancer want the most aggressive therapy available. Other survey results.

  • Prostate-cancer vaccine.  // Men's Health;Jul/Aug97, Vol. 12 Issue 6, p126 

    Presents information about prostate-cancer vaccine. Effectivity of the vaccine; Effect of a cancerous prostate cells left after surgery; Testing the vaccine in patients whose cancer has returned after surgery.

  • PSA results refute objections to perineal prostatectomy. Kuznar, Wayne // Urology Times;Jan95, Vol. 23 Issue 1, p22 

    Reports on the effectiveness of radical prostatectomy as a treatment for localized prostate cancer as indicated by postoperative prostate-specific antigen (PSA) levels. Criticism of perineal approach; Retropubic approach; Limiting factor to radical perineal prostatectomy.

  • Sr 89 injection eases prostate cancer pain.  // Urology Times;Dec95, Vol. 23 Issue 12, p17 

    Reports on an article published in the June 1993 issue of `Seminars in Oncology' about a drug that reduces the pain experienced by prostate cancer patients.

  • Concern grows over prostate cancer treatment options. Parkins, Troy // JNCI: Journal of the National Cancer Institute;6/15/94, Vol. 86 Issue 12, p897 

    Reports on the benefits and limitations of various treatment options for prostate cancer. Popularity of radical prostatectomy; Effectiveness of cryosurgery over radiation; Concerns of doctors on cryosurgery; Side effects of prostate cancer treatment.

  • Inhibition of prostate cancer metastasis: A critical challenge ahead. Linehan, W. Marston // JNCI: Journal of the National Cancer Institute;3/1/95, Vol. 87 Issue 5, p331 

    Editorial. Observes that there is no curative therapy for prostate cancer once it spreads beyond the prostate. Challenge to develop agents that will inhibit or prevent progression of recurrent or locally advanced prostate cancer; Investigation into the ability of naturally occurring agents.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics